ADC Therapeutics to Host Fourth Quarter and Year-End 2024 Financial Results Conference Call on March 27, 2025

Core Insights - ADC Therapeutics SA is a global leader in antibody drug conjugates (ADCs) and will host a conference call on March 27, 2025, to report financial results for Q4 and the year ended December 31, 2024 [1][2] - The company is advancing its proprietary ADC technology to improve treatment for patients with hematologic malignancies and solid tumors [3] - ADC Therapeutics' ZYNLONTA (loncastuximab tesirine-lpyl) has received accelerated approval from the FDA and conditional approval from the European Commission for treating relapsed or refractory diffuse large B-cell lymphoma [4] Company Overview - ADC Therapeutics is based in Lausanne, Switzerland, with operations in London and New Jersey [5] - The company is focused on developing multiple ADCs that are currently in clinical and preclinical stages [4] Upcoming Events - The conference call will provide operational updates and is accessible via a live webcast on the company's investor relations website [2]